Physician profile
Matthew Everett Bryan
NPI 1255379533
$974.13
in general payments reported to CMS, 2019-2025
21 companies · $98.36 in 2025
The $98.36 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $80.24 · 2021: $143 · 2022: $193 · 2023: $193 · 2024: $94.76 · 2025: $98.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.82 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $184.10 | 2019-2023 | |
| Janssen Biotech, INC. | $156.82 | 2021-2024 | Tremfya |
| Amgen INC. | $78.46 | 2021-2024 | Otezla |
| Lilly USA, LLC | $74.08 | 2019-2024 | Ebglyss |
| Pfizer INC. | $50.81 | 2019-2020 | |
| Abbvie INC. | $46.25 | 2019-2025 | |
| Misonix INC | $45.10 | 2020-2021 | |
| Galderma Laboratories, L.P. | $43.76 | 2019-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $39.13 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $33.07 | 2022 | |
| Incyte Corporation | $28.97 | 2022 | |
| Organogenesis INC. | $26.70 | 2025 | Affinity |
| Prugen, INC. Pharmaceuticals | $23.40 | 2019 | |
| Celgene Corporation | $21.43 | 2019 | |
| Smith+Nephew, INC. | $20.05 | 2025 | Collagenase Santyl |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $19.96 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Paratek Pharmaceuticals, INC. | $19.31 | 2022 | |
| Mayne Pharma Commercial LLC | $18.42 | 2023 | |
| Arcutis Biotherapeutics, INC. | $16.56 | 2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $14.44 | 2022 | |
| Genzyme Corporation | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.